on behalf of the SMART study group Background: Interruption of a non-nucleoside reverse transcriptase inhibitor (NNRTI)-regimen is often necessary, but must be performed with caution because NNRTIs have a low genetic barrier to resistance. Limited data exist to guide clinical practice on the best interruption strategy to use.
Introduction
Interruption of combination antiretroviral therapy is associated with an increased risk of all-cause mortality, AIDS and other serious non-AIDS events (renal, hepatic and cardiovascular disease) compared with continuous therapy, as recently demonstrated in the Strategies for Management of Antiretroviral Therapy (SMART) study [1] . Even so, there are still occasional circumstances in which patients may want, or need, to interrupt some or all of the antiretrovirals in their regimen. For example, women who take antiretroviral drugs to prevent vertical HIV-transmission may choose to discontinue therapy after delivery or may need to stop therapy if the drug supply is interrupted, particularly in resource-limited settings.
Antiretroviral drugs have different plasma and intracellular half-lives [2] . The plasma elimination half-lives of most nucleoside reverse transcriptase inhibitors (NRTIs) vary from 2-6 h, although the half-life of lamivudine is approximately 7 h, the half-life of emtricitabine approximately 10 h and the half-life of tenofovir approximately 15 h. The intracellular half-lives of NRTIs are longer than their plasma half-lives; however, they are still generally less than 9 h. The NRTIs with the longest intracellular half-lives are lamivudine triphosphate (i.e. between 11 and 15 h), emtricitabine triphosphate (i.e. approximately 39 h) and tenofovir diphosphate (i.e. between 12 and 15 h in activated lymphocytes and approximately 50 h in resting lymphocytes) [3] . Protease inhibitors also have plasma elimination half-lives that are less than 8 h, even when used with ritonavir boosting, except for darunavirritonavir, which has a higher half-life of approximately 15 h. The nonnucleoside reverse transcriptase inhibitors (NNRTIs), efavirenz and nevirapine, have much longer elimination half-lives than any other class of drugs, estimated to be between 35 and 45 h.
Efavirenz clearance has been shown to be particularly slow in persons carrying a G ! T substitution at position 516 of the cytochrome P450 (CYP) 2B6 gene, a polymorphism over-represented in persons of BlackAfrican descent. After discontinuation, plasma efavirenz concentrations in patients with 516 GG, GT and TT genotypes are predicted to exceed the 95% inhibitory concentration for wild-type virus (i.e. 46.7 ng/ml) for a median of 5.8 days [interquartile range (IQR) : 4.4-8.3 days], 7.0 days (IQR: 5.0-8.0 days) and 14 days (IQR: 11.1-21.2 days), respectively [4] .
Given the prolonged half-life of current NNRTIs, there is a concern that simultaneous interruption of all antiretrovirald in an NNRTI-containing regimen may lead to a period in which plasma contains only the NNRTI. Monotherapy with an NNRTI is insufficient to maintain virological suppression, and consequently the risk of drug resistance increases [5] . The NNRTIs, nevirapine and efavirenz, have a low genetic barrier, as only one mutation is required to confer high-level drug resistance, so the consequences of resistance development for these drugs are particularly serious. This has led to the suggestion that the NNRTI component of a regimen could be stopped earlier than other antiretrovirals in the regimen in order to avoid the potential for NNRTI monotherapy [6] . The emergence of drug-resistance mutations may still be a problem in patients who interrupt treatment using these other strategies because they were predominantly defined on pharmacokinetic principles with little if any clinical data to support them [7, 8] .
In this report, we analyse data from a large trial of treatment interruptions (SMART) and examine the rates of viral resuppression among patients who interrupt an NNRTI-containing regimen with HIV-RNA of 400 copies/ml or less and then restart an NNRTI after the interruption. The detection of drug-resistance mutations 2 months after initiating a treatment interruption is also described for these patients.
Patients and methods

Study population
From January 2002, 5472 patients were randomized to either CD4 þ guided treatment interruptions (N ¼ 2720, the drug conservation arm), or to continuous therapy (N ¼ 2752, the viral suppression arm) in SMART. Patients were more than 13 years of age, not pregnant or breastfeeding and had CD4 þ cell counts more than 350 cells/ml at study entry. The trial was stopped prematurely on 11 January 2006 after an interim analysis showed that not only were more deaths and AIDS events occurring in the drug conservation arm, but that serious non-AIDS events were also occurring more frequently [1].
We included patients who were on an NNRTIcontaining regimen, were randomized to the drug conservation arm of SMART and had HIV-RNA of 400 copies/ml or less at the time of their treatment interruption. These patients have already achieved viral suppression on an NNRTI-containing regimen and are likely to be those harbouring little resistance in their viral populations. Clinicians were permitted to interrupt a regimen on the basis of their local practice standards but were advised to avoid interrupting all antiretrovirals simultaneously (simultaneous interruption). The protocol recommended two alternative strategies: a staggered interruption (i.e. interrupting the NNRTI while maintaining NRTIs for an average period of 7 days, though a longer interval of 10-21 days was recommended for Blacks and Hispanics), or they could replace the NNRTI with a boosted protease inhibitor for a short periodgiven their shorter half-lives and higher genetic barrierand then interrupt all drugs (switched interruption). The recommendation to use other strategies rather than a simultaneous interruption was implemented in 2003 when it was clear that resistance could be an issue. However, 20.2% of patients who interrupted an NNRTI in SMART still underwent a simultaneous interruption. Patients with a simultaneous interruption were compared with patients who interrupted an NNRTI using each of the other strategies because simultaneous interruptions are medically discouraged [9, 10] .
Laboratory methods
Follow-up visits in SMARTwere scheduled to take place after 1 month, 2 months and every 2 months thereafter for the first year and every 4 months in the second and subsequent years of follow-up. At each visit, patients had their treatment history recorded and their CD4 þ cell counts and plasma HIV-RNA levels measured. The resistance analysis was restricted to viruses from patients who had plasma HIV-RNA of at least 1000 copies/ml in the 2 months following a treatment interruption, but before resuming therapy. This time-point was selected as one during which NNRTI mutations, if present, are most likely to be detected because NNRTI mutations are expected to emerge fairly rapidly during NNRTI monotherapy or during a treatment interruption [11] . In addition, we did not study resistance at a later timepoint because, in the absence of therapy, the virus population is predicted to be dominated by wild-type virus and consequently any mutations that arise during the interruption are less likely to be identified. A standard genotyping assay (TRUGENE; Visible Genetics, Suwanee, Georgia, USA) was used. Sequence data were translated into amino acid substitutions (full or mixed) from a reference clade B strain (i.e. HXB2) for both reverse transcriptase and protease.
Statistical analysis
Baseline and prebaseline characteristics were examined for patients who interrupted an NNRTI using each of the interruption strategies. For these comparisons, baseline was considered to be the time of the treatment interruption. Categorical variables were compared using x 2 and Fisher's exact tests. For continuous variables, we used either analysis of variance (ANOVA) models or Kruskal-Wallis tests depending on the distribution.
The proportion of patients with HIV-RNA of 400 copies/ml or less, 4-8 months after restarting therapy, was investigated using logistic regression analysis, irrespective of whether patients experienced a treatment change after resuming treatment (as an intention-to-treat analysis). In order to account for the fact that the patient may have changed regimens because of underperformance of the NNRTI, and consequently there may be misrepresentation of the overall impact of NNRTIresistance, we also performed a switch equals failure analysis. Here, a switch away from the NNRTI that was restarted was considered to constitute failure.
We then examined the number and type of resistance mutations (i.e. specific mutations and class of mutation) in patients with resistance data available. We used Fisher's exact tests to compare the occurrence of new mutations according to the NNRTI-interruption strategy, without adjustment for multiple comparisons. Unadjusted logistic regression analysis was also used. All statistical analyses were performed using STATA software (StataCorp. 2007. Stata Statistical Software: Version 9.2/SE; College Station, Texas, USA).
Results
Patient characteristics
Of the 2720 patients who were randomized to the drug conservation arm of SMART, there were 984 (36.2%) who discontinued an NNRTI and had HIV-RNA of 400 copies/ml or less at the start of their treatment interruption, referred to here as baseline. The 984 patients were primarily men (76%) and 27% had a Centres for Disease Control (CDC) category stage C (Table 1 ).
The analysis described in this report mainly focuses on patients who interrupted an NNRTI and had their interruption strategy recorded. From the 984 patients, 717 (72.9%) had their interruption strategy recorded ( Fig. 1 ). There were no differences in baseline characteristics between these patients and the 267 patients who did not have their interruption strategy recorded (data not shown).
Baseline characteristics for 717 patients are outlined in Table 1 . As interruption guidelines were amended after SMART began, patients who interrupted therapy earlier were more likely to undergo simultaneous interruption compared with either staggered or switched interruption (P < 0.001). Patients who underwent a simultaneous interruption also had higher HIV-RNA levels immediately prior to the interruption compared with patients who interrupted treatment using alternative strategies (P < 0.001). 
Viral resuppression after restarting nonnucleoside reverse transcriptase inhibitors
There were 688 patients who restarted an NNRTIcontaining regimen during follow-up and had at least one HIV-RNA measurement 4-8 months after the restart (Fig. 1 ). Of these, 642 (93.3%) patients restarted the same NNRTI as they interrupted, 595 (86.5%) stayed on the NNRTI they restarted for at least 8 months following the restart and 515 (74.9%) patients had their interruption strategy noted.
All 688 patients were initially included in these analyses, irrespective of whether their interruption strategy was known. In an intention-to-treat analysis, in which treatment changes after resumption of therapy were not accounted for, the percentage of patients who achieved viral resuppression (i.e. reached HIV-RNA 400 copies/ml) according to the NNRTI that was restarted was 90.0% (404/449), 82.2% (194/236) and 100% (3/3) for patients who reinitiated efavirenz, nevirapine and delarvidine, respectively (P ¼ 0.012).
Although efavirenz, nevirapine and delarvidine were restarted in these patients, only 88.1% (356/404), 88.7% (172/194) and 100% (3/3), respectively, were using their NNRTI at the time of viral resuppression. From the 87 patients who did not reach viral resuppression in the 8 months following resumption of therapy, there were 68.9% (31/45) who restarted efavirenz and 78.6% (33/42) who restarted nevirapine who were using their NNRTI at the time the resuppression rate was determined. Overall, 89.3% (531/595) patients who remained on the same regimen reached viral resuppression and 75.3% (70/93) patients who switched regimens achieved viral resuppression (P < 0.0001).
Physicians may capture a lack of viral response early in patients who resume a regimen that does not function effectively. As a result, patients with poor virological responses are likely to be those who experience treatment changes to their regimens. If, instead, we consider all patients who experience changes to their regimens as failures (i.e. they have a 4-8 month HIV-RNA>400 cocopies/ml), the percentage of patients who achieved viral resuppression according to the NNRTI that was reinitiated was 79.3% (356/449), 72.9% (172/236) and 100% (3/3) for patients who reinitiated efavirenz, nevirapine and delarvidine, respectively (P ¼ 0.11).
Next we focused on the 515 patients who had their initial interruption strategy recorded. The median (IQR) time from NNRTI interruption to NNRTI reinitiation was 20.7 (11.7-40.8), 25.6 (12.4-45.0) and 20.3 (10.7-43.0) weeks for patients who underwent a simultaneous interruption, a staggered interruption and a switched interruption, respectively (P ¼ 0.46). Significant differences existed in the proportion of patients with HIV-RNA of 400 copies/ml or less 4-8 months after restarting therapy according to the interruption strategy (82.7% of patients with a simultaneous interruption versus 90.2% of those with a staggered interruption and 94.6% of those with a switched interruption, P ¼ 0.02). In a multivariable logistic regression model, the odds ratio (OR) for achieving HIV-RNA resuppression was1.94 (1.02-3.69) for patients with a staggered interruption and 3.64 (1.37-9.64) for patients with a switched interruption compared with patients with a simultaneous interruption, indicating a benefit of either or both of these two strategies. Race, CD4
þ cell counts at the time of the treatment interruption, hepatitis B coinfection and hepatitis C coinfection were not independent predictors of response.
Detection of drug-resistance mutations
Out of the 717 patients who were fully virologically suppressed at baseline and had their treatment interruption strategy recorded, 141 (19.7%) had resistance data available in the 2 months following a treatment interruption ( Fig. 1 ): 61 underwent a simultaneous interruption, 56 underwent a staggered interruption and 24 underwent a switched interruption. These patients were broadly reflective of all patients in SMARTwho interrupted an NNRTI. Patients with a resistance test were more likely to be black (i.e. 38% versus 21%; P < 0.0001) and they had lower CD4 þ nadir counts [a median (IQR) of 200 (78, 299) versus 237 (149, 348); P ¼ 0.0004] compared with patients who did not have a resistance test available. In patients with resistance data, the only difference in baseline characteristics according to the NNRTI interruption strategy was that patients with simultaneous interruption were more likely to have a CDC category C illness at baseline and that these patients were also more likely to have interrupted treatment at an earlier time-point (Table 1 ).
In the 2 months following a treatment interruption, NRTI, NNRTI and/or protease inhibitor-specific mutations were detected in the predominant virus of 23 (16%), 18 (13%) and 11 (8%) of 141 patients, respectively, according to the 2007 International AIDS Society (IAS)-USA mutations lists [12] . No significant differences were observed in the proportion of classspecific mutations that were detected according to the method of stopping the NNRTI (Table 2) .
Although not significant, NNRTI mutations were less likely to be detected in patients who had a staggered or switched interruption compared with those with a simultaneous interruption [Odds ratio for the detection of an NNRTI mutation: OR (95% confidence interval, CI): 0.57 (0.21-1.53) for staggered or switched interruption versus simultaneous interruption, P ¼ 0.29], and NRTI mutations were more likely to be detected in the predominant virus of patients who underwent a staggered or switched interruption compared with those with a simultaneous interruption [OR for the detection of an NRTI mutation (95% CI): 1.23 (0.49-3.05) for staggered or switched interruption versus simultaneous interruption, P ¼ 0.66]. Other factors such as CD4
þ cell counts and HIV-RNA levels at the time of the treatment interruption, hepatitis coinfection, race, the NNRTI restarted and the mode of infection were not predictors of resistance in this population. Mutations that are selected by patients who interrupted each NNRTI are described separately in Table 2 .
We explored the detection of specific-resistance mutations and investigated how many drug classes were compromised by the presence of resistance in these patients. No significant differences were seen in these comparisons, but the number of mutations that were detected overall was small so we only have limited power to illustrate any differences if they truly exist ( Table 2 ).
Viral resuppression according to mutations detected in the resistance test
Out of the 141 patients with resistance data available, there were 101 (71.6%) who restarted an NNRTI according to protocol recommendations and have HIV-RNA data available 4-8 months after resuming therapy (42 patients with simultaneous interruption, 40 patients with staggered interruption and 19 patients with switched interruption); 83 (82.2%) of these patients reached an HIV-RNA of 400 copies/ml or less a maximum of 8 months after the restart. The median (IQR) HIV-RNA at the time of the restart was 4.55 (4.04-5.00) log 10 copies/ ml for patients with a simultaneous interruption, 4.61 (4.35-5 .08) log 10 copies/ml for patients with a staggered interruption and 4.88 (4.53-5.04) log 10 copies/ml for patients with a switched interruption.
Among patients who restarted an NNRTI, significantly fewer patients who had a mutation detected [18 of 26 (69.2%) ] achieved viral resuppression compared with those who did not have any mutations in their resistance tests [65 of 75 (86.7%); P ¼ 0.05]. The proportion of patients who reached virological resuppression after restarting therapy did not differ significantly according to the class of resistance mutations that were present in the follow-up resistance test. Six out of nine (66.7%) patients with a virus containing NRTI mutations only, seven out of nine (77.8%) patients with a virus containing NNRTI mutations, five out of eight (62.5%) patients with a virus containing protease inhibitor mutations and 65 of 75 (86.7%) patients with a virus containing no IAS-USA mutations, achieved viral load resuppression 4-8 months after restarting therapy.
Discussion
The SMART study contains the largest database of patients who were virologically suppressed on an NNRTI-containing regimen and interrupted their antiretrovirals according to one of three predefined strategies (one of which was actively discouraged).
Although SMART was a randomized clinical trial, this article represents an analysis of observational data as selection of the interruption strategy was at the discretion of the treating clinician. Although resuppression rates were high in this study (i.e. 89.7% of patients achieved viral resuppression), we have shown that interruption from an NNRTI-containing regimen does not always result in complete viral resuppression once therapy is resumed. We have also provided some evidence that, if a patient is interrupting an NNRTI-containing regimen, it is particularly important not to interrupt all antiretroviral drugs simultaneously, but to undergo a staggered or switched interruption instead. There also appears to be some evidence that a staggered interruption may be worse than a switched interruption, an observation that is biologically plausible. However, as these comparisons were performed on a small number of patients, further evidence is required to state this conclusively.
Drug-resistant HIV has been shown to emerge during periods of increased HIV replication when drug concentrations are present but suboptimal [6, [13] [14] [15] [16] . Although the absolute number of mutations detected in our study was small, NNRTI mutations were observed in a relatively high proportion of patients 2 months after undergoing a treatment interruption. Even though we cannot exclude the possibility that these mutations were present before therapy interruption, these results emphasize the need for treatment interruptions to be performed with caution (and only when essential), in order to avoid the emergence of NNRTI-specific mutations that compromise future treatment options. Among patients who restarted therapy, significantly fewer patients who had a mutation in their resistance test achieved viral resuppression (69.2%) compared with those who did not have any mutations in their resistance test (86.7%; P ¼ 0.05), re-emphasizing the need to interrupt NNRTIbased regimens wisely. Overall, the absolute number of mutations that were detected in the reverse transcriptase and protease genes was small for patients who interrupted an NNRTI using each interruption strategy. High rates of resistance to NNRTIs were seen in the TRIVACAN trial, in which resistance was examined among patients undergoing a treatment interruption in sub-Saharan Africa, though the method of interrupting the NNRTI was not studied in detail [17] . The Istituto Superiore di Sanita-Pulsed Antiretroviral Therapy (ISS-PART) study [18] demonstrated a low risk of mutation emergence for patients interrupting an NNRTI-containing regimen, but a higher risk among patients who interrupt a regimen including an unboosted protease inhibitor. NNRTI resistance emergence has been associated with NNRTI drug levels prior to the treatment interruption, with drug concentrations close to the lower limit of the therapeutic range associated with more resistance emergence [19] .
In our study, NNRTI-mutations were less likely to arise after a staggered or switched interruption compared with patients with a simultaneous interruption, but the number of patients in whom resistance mutations were detected was too small for any of the differences to reach statistical significance. Although the trend was not significant, a staggered or switched interruption was still associated with nearly half the odds of detecting an NNRTI mutation in the predominant virus population compared with a simultaneous interruption.
Patients who withdraw consent to continue in trials or become lost to follow-up are likely to remain off treatment until they return to clinical care. These data give us some insight into the risk of mutation development (and hence the prevalence of resistance) in patients who drop out of antiretroviral programmes worldwide. They also indicate the likelihood that these patients will experience virological suppression if a similar regimen is restarted at a later stage.
This analysis only looks at the risk of resistance emergence after a first treatment interruption in SMART. Repeat interruptions of the same regimen could increase the risk of resistance [14] . Some patients show little evidence of resistance during a first interruption, but an elevated risk after a second or third interruption of the same regimen [14] . Conversely, Arnedo-Valero et al. [20] showed that the number of mutations did not increase with the number of interruptions. In SMART, patients could reinitiate the same regimen after their treatment interruption, but as the study was terminated prematurely, it was not possible to examine the relationship between mutation emergence and further interruption cycles in more detail.
It is not known whether the mutations observed in this study are attributable to the occurrence of new mutations or to the reappearance of previously existing mutations.
As all of these patients had an HIV-RNA of 400 copies/ ml or less at baseline, it was not possible to perform genotypic resistance testing. Our assumptions that patients with an HIV-RNA of 400 copies/ml or less at baseline had no NNRTI mutations in their virus population may not be correct [21] .
This study used population sequencing, rather than more sensitive methods for identifying mutants that are present as minority viral strains, for assessing drug resistance. If ultrasensitive genotyping analyses (e.g. allele-specific PCR, clonal or single genome sequencing) had been used, more NNRTI mutations (i.e. low-frequency drugresistant variants) may have been detected [22, 23] .
Patients may appear to have wild-type strain at the time of their resistance test even if mutations in proviral DNA are present [13] . It is, therefore, possible that our data underestimate the incidence of resistance mutations as a result of the treatment interruption [13] .
To conclude, the method of interrupting an NNRTI and the NNRTI restarted may impact on the chances of viral resuppression on an NNRTI-containing regimen after a treatment interruption. NNRTI mutations were observed in a relatively high proportion of patients 2 months after a treatment interruption. Although no significant differences were observed between stopping strategies in the number, type or class of mutation that emerged, there was a consistent trend for more mutations to emerge when a simultaneous interruption strategy was used. The simultaneous interruption of all antiretroviral drugs in a suppressive NNRTI/NRTI-containing regimen may negatively impact on the response to the future use of antiretrovirals because of the emergence of resistance mutations. These data provide further evidence for negative consequences of interruption of an NNRTIcontaining regimen and further support the recommendation to avoid interruption entirely. When such interruptions are essential, these data suggest that a staggered or switched approach when interrupting an NNRTI may reduce the risk of resistance emerging.
